开发并验证基于循环成纤维细胞活化蛋白的新型预测模型,改善代谢性肝病人群的纤维化风险分层

Ziqi Vincent Wang, Badwi B Boumelhem, Torsten Pennell, William W Bachovchin, Geraldine Ooi, Jacob George, Mohammed Eslam, Leon A Adams, Pieter van der Veken, Jack Hung-Sen Lai, Sarah Poplawski, Kate Brewer, Hui Emma Zhang, Geoffrey W McCaughan, Avik Majumdar, Mark D Gorrell
{"title":"开发并验证基于循环成纤维细胞活化蛋白的新型预测模型,改善代谢性肝病人群的纤维化风险分层","authors":"Ziqi Vincent Wang, Badwi B Boumelhem, Torsten Pennell, William W Bachovchin, Geraldine Ooi, Jacob George, Mohammed Eslam, Leon A Adams, Pieter van der Veken, Jack Hung-Sen Lai, Sarah Poplawski, Kate Brewer, Hui Emma Zhang, Geoffrey W McCaughan, Avik Majumdar, Mark D Gorrell","doi":"10.1101/2024.07.19.24310730","DOIUrl":null,"url":null,"abstract":"Objective: Metabolic fatty liver disease drives chronic liver injury leading to fibrosis. This study aimed to establish a model utilising serum circulating fibroblast activation protein (cFAP) to diagnose advanced fibrosis in patients with fatty liver disease.\nDesign:\nTwo retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n=160) and external validation cohorts (n=342), with prevalence of histologic advanced fibrosis (F3/F4) of 20% and 11%, respectively. A marker of activated mesenchymal fibrogenic cells, cFAP, was measured using our single-step enzyme assay. A predictive model, FAP Index, containing age, type 2 diabetes, alanine transaminase and ordinal cFAP was developed using logistic regression. Diagnostic accuracy of FAP Index was assessed on a single and then sequential basis.\nResults:\nFAP Index AUROC was 0.875 (95% CI 0.813-0.938) in the training cohort and 0.841 (95% CI 0.776-0.906) in the validation cohort. Low cut-off -1.68 (Sensitivity 80.0%, negative predictive value 95.5%) and high cut-off +0.953 values (Specificity 97.7%, positive predictive value 88.9%) excluded and diagnosed advanced fibrosis, respectively. In the validation cohort, FAP Index then FIB-4 reduced indeterminate results by one-third compared to FIB-4 alone. Whereas FAP-Index followed by NFS (NAFLD Fibrosis Score) resulted in a reduction of indeterminate results by 70% compared to NFS alone. Conclusion:\nFAP Index is a novel, rapid, robust, inexpensive diagnostic tool for advanced fibrosis in metabolic fatty liver disease. Applying FAP Index followed by FIB-4 or NFS facilitates accurate risk-stratification of patients by greatly reducing the frequency of indeterminate results compared to FIB-4 or NFS alone, without compromising negative predictive value.","PeriodicalId":501258,"journal":{"name":"medRxiv - Gastroenterology","volume":"24 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and validation of a novel circulating fibroblast activation protein - based predictive model to improve fibrosis risk stratification in metabolic liver disease population\",\"authors\":\"Ziqi Vincent Wang, Badwi B Boumelhem, Torsten Pennell, William W Bachovchin, Geraldine Ooi, Jacob George, Mohammed Eslam, Leon A Adams, Pieter van der Veken, Jack Hung-Sen Lai, Sarah Poplawski, Kate Brewer, Hui Emma Zhang, Geoffrey W McCaughan, Avik Majumdar, Mark D Gorrell\",\"doi\":\"10.1101/2024.07.19.24310730\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Metabolic fatty liver disease drives chronic liver injury leading to fibrosis. This study aimed to establish a model utilising serum circulating fibroblast activation protein (cFAP) to diagnose advanced fibrosis in patients with fatty liver disease.\\nDesign:\\nTwo retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n=160) and external validation cohorts (n=342), with prevalence of histologic advanced fibrosis (F3/F4) of 20% and 11%, respectively. A marker of activated mesenchymal fibrogenic cells, cFAP, was measured using our single-step enzyme assay. A predictive model, FAP Index, containing age, type 2 diabetes, alanine transaminase and ordinal cFAP was developed using logistic regression. Diagnostic accuracy of FAP Index was assessed on a single and then sequential basis.\\nResults:\\nFAP Index AUROC was 0.875 (95% CI 0.813-0.938) in the training cohort and 0.841 (95% CI 0.776-0.906) in the validation cohort. Low cut-off -1.68 (Sensitivity 80.0%, negative predictive value 95.5%) and high cut-off +0.953 values (Specificity 97.7%, positive predictive value 88.9%) excluded and diagnosed advanced fibrosis, respectively. In the validation cohort, FAP Index then FIB-4 reduced indeterminate results by one-third compared to FIB-4 alone. Whereas FAP-Index followed by NFS (NAFLD Fibrosis Score) resulted in a reduction of indeterminate results by 70% compared to NFS alone. Conclusion:\\nFAP Index is a novel, rapid, robust, inexpensive diagnostic tool for advanced fibrosis in metabolic fatty liver disease. Applying FAP Index followed by FIB-4 or NFS facilitates accurate risk-stratification of patients by greatly reducing the frequency of indeterminate results compared to FIB-4 or NFS alone, without compromising negative predictive value.\",\"PeriodicalId\":501258,\"journal\":{\"name\":\"medRxiv - Gastroenterology\",\"volume\":\"24 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.07.19.24310730\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.07.19.24310730","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的:代谢性脂肪肝会造成慢性肝损伤,导致肝纤维化。本研究旨在建立一种利用血清循环成纤维细胞活化蛋白(cFAP)诊断脂肪肝患者晚期肝纤维化的模型。设计:研究了两个从三级肝病诊所招募的回顾性队列,分别作为训练队列(n=160)和外部验证队列(n=342),其组织学晚期肝纤维化(F3/F4)发生率分别为20%和11%。活化间质纤维化细胞的标志物 cFAP 是用我们的单步酶测定法测量的。利用逻辑回归建立了一个预测模型,即 FAP 指数,其中包含年龄、2 型糖尿病、丙氨酸转氨酶和 cFAP 的序数。结果:FAP 指数的 AUROC 在训练队列中为 0.875(95% CI 0.813-0.938),在验证队列中为 0.841(95% CI 0.776-0.906)。低临界值-1.68(灵敏度 80.0%,阴性预测值 95.5%)和高临界值+0.953(特异性 97.7%,阳性预测值 88.9%)分别排除和诊断了晚期纤维化。在验证队列中,与单独使用 FIB-4 相比,先使用 FAP 指数再使用 FIB-4 可将不确定结果减少三分之一。而 FAP 指数和 NFS(非酒精性脂肪肝纤维化评分)可将不确定结果减少 70%。结论:FAP 指数是一种新颖、快速、可靠、廉价的代谢性脂肪肝晚期纤维化诊断工具。与单独使用 FIB-4 或 NFS 相比,使用 FAP 指数和 FIB-4 或 NFS 可大大减少不确定结果的出现频率,从而有助于对患者进行准确的风险分层,而不会影响阴性预测值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development and validation of a novel circulating fibroblast activation protein - based predictive model to improve fibrosis risk stratification in metabolic liver disease population
Objective: Metabolic fatty liver disease drives chronic liver injury leading to fibrosis. This study aimed to establish a model utilising serum circulating fibroblast activation protein (cFAP) to diagnose advanced fibrosis in patients with fatty liver disease. Design: Two retrospective cohorts recruited from tertiary hepatology clinics were studied as training (n=160) and external validation cohorts (n=342), with prevalence of histologic advanced fibrosis (F3/F4) of 20% and 11%, respectively. A marker of activated mesenchymal fibrogenic cells, cFAP, was measured using our single-step enzyme assay. A predictive model, FAP Index, containing age, type 2 diabetes, alanine transaminase and ordinal cFAP was developed using logistic regression. Diagnostic accuracy of FAP Index was assessed on a single and then sequential basis. Results: FAP Index AUROC was 0.875 (95% CI 0.813-0.938) in the training cohort and 0.841 (95% CI 0.776-0.906) in the validation cohort. Low cut-off -1.68 (Sensitivity 80.0%, negative predictive value 95.5%) and high cut-off +0.953 values (Specificity 97.7%, positive predictive value 88.9%) excluded and diagnosed advanced fibrosis, respectively. In the validation cohort, FAP Index then FIB-4 reduced indeterminate results by one-third compared to FIB-4 alone. Whereas FAP-Index followed by NFS (NAFLD Fibrosis Score) resulted in a reduction of indeterminate results by 70% compared to NFS alone. Conclusion: FAP Index is a novel, rapid, robust, inexpensive diagnostic tool for advanced fibrosis in metabolic fatty liver disease. Applying FAP Index followed by FIB-4 or NFS facilitates accurate risk-stratification of patients by greatly reducing the frequency of indeterminate results compared to FIB-4 or NFS alone, without compromising negative predictive value.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信